Krystal Biotech (KRYS) Finished Goods (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Finished Goods data on file, last reported at $12.4 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 109.53% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (up 109.53% YoY), and the FY2025 full-year result was $9.3 million, up 338.05% from the prior year.
• Finished Goods advanced to $12.4 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $12.4 million in Q1 2026 to a low of $161000.0 in Q1 2024.
• A 4-year average of $4.4 million and a median of $2.7 million in 2024 frame the typical range for Finished Goods.
• Peak annual rise in Finished Goods reached 3563.35% in 2025, while the deepest fall reached 4.03% in 2025.
• Tracing KRYS's Finished Goods over 4 years: stood at $627000.0 in 2023, then surged by 239.07% to $2.1 million in 2024, then soared by 338.05% to $9.3 million in 2025, then soared by 32.7% to $12.4 million in 2026.
• Business Quant data shows KRYS's Finished Goods at $12.4 million in Q1 2026, $9.3 million in Q4 2025, and $7.3 million in Q3 2025.